teriophage TP-68 to detect potential antitumor compounds acting on DNAor topoisomerases4). In order to discover the new lead compounds targeting on DNA or DNA topoisomerases, we have screened cultures of actinomycetes and fungi for their ability to inhibit selectively the growth of bacteriophage TP-68 at the concentration that shows no apparent antibacterial activity against NUB3620. In the course of microbial screening, strain KYI1768 was identified to produce active metabolites. We described here production including fermentation and isolation, and biological activity of novel pyrrole-amide antitumor antibiotics, pyrronamycin A and B, produced by Streptomyces sp.
The producing organism KYI 1768 was isolated from a soil sample collected in Okazaki city, Aichi prefecture, Japan and assigned to the Streptomyces sp. Fermentation was carried out at 25°C for 42 hours with appropriate aeration and agitation in 30-liter jar fermenter containing the 15 liters of culture medium consisting of glycerol 5%, (Table  1) , while distamycin A (Sigma) did not show activity at amounts up to lO^g/disc. Adriamycin and m-AMSA, both of which act on topoisomerase II, showed antibacteriophage activity in this assay system4), while pyrronamycin A and B did not show the effect on mammaliantopoisomerase I or II in vitro and in cells (data not shown).
In the absence of topoisomerases, pyrronamycin B induced a band shift of supercoiled pBR322 in a dose dependent manner as shown in Evaluation on murine tumor models in vivo revealed that pyrronamycin B showed antitumor activity against sarcoma 180 (T/C 0.44) at a single dose of 0.38mg/kg and also induced marginal regression of human lung carcinoma A549 (T/C 0.51) inoculated into nude mice at a single dose of 0.25mg/kg. Distamycin A is known to be inactive as antitumor drug presumably due to the non-alkylating property. However, it has been reported that a synthetic distamycin A analog bearing DNA-alkylating moiety, FCE2451 7, showed prominent antitumor activity in murine tumor models and is under clinical evaluation10'11}. These results imply that a stable complex formation of pyrronamycin A and B with DNAcould contribute to the superior biological activity of these antibiotics to that of Sarcoma 180 cells (5X 106cells/mouse) were inoculated sc on day 0. Drugs were administrated iv on each day and the tumor volume was measured on day 7.
* Numberof toxic mouse death.
